Shenzhen Targetrx Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety covalently linked to Raf kinase B (V600E mutant)-targeting moiety through linker reported to be useful for the treatment of cancer.
Shanghai Xianxiang Medical Technology Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety coupled to an EGFR (HER1; erbB1) mutant-targeting moiety through a linker reported to be useful for the treatment of cancer.
Sunrise Oncology (Hong Kong) Ltd. has identified molecular glues acting as phosphodiesterase PDE3A/SLFN12 interaction inducers reported to be useful for the treatment of cancer.
Aurigene Oncology Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase protein binding moiety covalently linked to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) binding moieties through a linker reported to be useful for the treatment of cancer.
While immunotherapy targeting PD-1 or its ligand PD-L1 has transformed cancer treatment by overcoming T-cell exhaustion, only a minority of patients achieves durable responses after treatment.
Oncolytic viruses are being actively explored as cancer therapies because they preferentially infect tumor cells and cause their lysis. At the same time, the viruses can accommodate transgenes that can stimulate anti-cancer responses in the local tumor microenvironment.
The Ohio State University has synthesized dual specificity protein kinase TTK (MPS1; MPS1L1) inhibitors reported to be useful for the treatment of cancer.
C4 Therapeutics Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to a Raf kinase B (V600E mutant)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer.
The U.K. National Institute for Health and Care Excellence (NICE) opened a late-stage assessment for drug-eluting stents (DES) with an eye toward costs, advising clinicians that they should implant the least expensive DES unit that is clinically appropriate for that patient while the assessment is underway.
The detection of metastases in Merkel cell carcinoma (MCC) requires additional testing, such as pancytokeratin (panCK) or CK20, with no guarantee of success. Recent findings have identified transcription factor SOX11 and insulinoma-associated protein 1 (INSM1) as sensitive nuclear neuroendocrine markers, but their usefulness in MCC has not been proven.
